Innovative Therapy of Rheumatic Diseases and Infections: Modern Aspects. Part 3. Interleukin-6 Inhibitors

The problem of comorbid infections remains at the center of attention in modern rheumatology. The third part of this review presents current data on the frequency and localization of the major infections in patients with rheumatological disorders treated with interleukin-6 inhibitors (IL-6i). Both randomized controlled trials and experience with the use of IL-6 inhibitors, primarily tocilizumab, in real-world clinical practice indicate that these drugs increase the risk of opportunistic and serious bacterial infections to the same extent as other genetically engineered biological drugs. An individualized approach to treatment, prediction of biomarkers, management of high‑risk groups, and assessment of drug interactions are key factors determining the safety of using IL-6 inhibitors.